Memorandum

|  |  |
| --- | --- |
| To: | **State Employee Health Plan of Kansas** |
| From: | Kautook Vyas, PharmD |
| Date: | August 31, 2020 |
| Re: | **Review of formulary impact reports from Humana and SilverScripts**  |

The State Employee Health Plan of Kansas (SEHP) requested Segal assist in obtaining formulary impact reports for their Pharmacy Part D program. In conversation with SEHP, Segal submitted to the two vendors identified, Humana and SilverScript, the top 100 medications by volume utilized by plan members year to date (YTD) through June 2020.

The top 100 drug list by volume provided by Envision contained the following components: drug name, formulary status, tier indication, script count, total gross cost, utilizing member count, and market share. Detailed member information was not provided nor was claims data that did not make the top 100 medications by volume.

## Formulary Impact

Below are the summary charts that highlight the results of the analysis provided by Humana and SilverScript on a percent of individual prescriptions.

|  |  |  |  |
| --- | --- | --- | --- |
|  | Humana | SilverScript (premier) | SilverScript (value-classic) |
| No Change | 85% | 90.11% | 64.97% |
| Positive | 15% | 6.95% | 1.22% |
| Negative | 0.00% | 2.95% | 33.81% |
| Excluded | 0.00% | 0.00% | 0.00% |
| Total | 100% | 100% | 100% |

## Observations

The table above shows the positive, negative, and excluded medications represented as a percentage of the top 100 prescriptions by volume utilized by plan members through June of 2020. Positive impact indicates members will experience a lower copayment for the medications reviewed while negative represents members will have to pay a higher copay. Excluded indicates medications that would no longer be covered. For the current vendors no medications were excluded meaning access to the top 100 medication by volume would not be limited.

The SilverScript (value-classic) formulary seems to indicate the highest level of negative impact meaning there would be prescriptions that would result in a high member cost share based on plan design. Humana indicated zero negative impact while the SilverScript (premier) indicated a impact of 2.95%.

The vendors did not indicate a dollar value for the cost share that would be increased per individual member as specific member data was not made available for review. It is also important to note that members may have one medication impacted in a positive manner while having another medication impacted in a negative manner with a higher cost share. Vendors also did not provide the names of clinical alternatives in the case of impact however indicate all medications will have a clinically appropriate alternative. SilverScript did provide impact information for an alternative plan however it was not included in this review as that analysis is still pending.